This article explores the 20 most expensive stocks insiders are dumping in March. Previously, we covered the 15 cheapest stocks insiders are buying in March.
After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon. On Tuesday, Trump provided an update on tariffs, saying they will likely be more “lenient than reciprocal,” suggesting a more relaxed approach, reports CNBC.
As investors process daily market developments, uncertainty continues to impact the market. In these periods, insider trading often attracts attention, as purchases of company stock by executives may suggest confidence in the company’s future. However, insider selling doesn’t necessarily imply a lack of faith—it may be driven by personal financial needs or a desire for diversification. Executives frequently rely on pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it should be evaluated in the context of a company’s financial health, market trends, and industry changes.
The trading floor of Pacific Investment Management Company LLC with traders focusing on the global fixed income markets.
What are some of the most expensive stocks insiders have been selling this month so far? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least three insiders had sold shares in March. From there, we ranked the 20 stocks with the highest average price per share in times of sales.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
With each stock, we note the average price per share of these sales and the stock’s market capitalization. Let’s take a look at the 20 most expensive stocks insiders are dumping in March.
20. Essex Property Trust, Inc. (NYSE:ESS)
Market Capitalization: $21.00 billion
Essex Property is a real estate investment trust (REIT) that owns and manages over 62,000 apartment homes across the West Coast, including Southern California, the San Francisco Bay Area, and Seattle. The company focuses on strategic acquisitions and developments to optimize its portfolio, targeting strong job growth and innovation in these markets. Essex is a leading choice for apartment investments and is part of the S&P 500.
For the full year of 2024, Essex Property reported a net income per diluted share of $11.54 compared to $6.32 in 2023. For the full year 2024, the company acquired or increased its ownership interest in 13 apartment communities for a total contract price of $1.4 billion on a gross basis and disposed of one apartment community for a contract price of $252.4 million on a gross basis. For the full year 2024, the company received cash proceeds of $108.8 million from redemptions of structured finance investments yielding a weighted average return rate of 10.4%.
This month, five insiders, including the CEO and CFO, sold around $6.78 million worth of Essex Property shares at an average price of $314.94 per share. Year-to-date, the stock is up 6.53%, trading at $304.07 per share. Over the past 12 months, Essex Property shares returned 28.11% to its investors.
Twenty analysts rate Essex Property stock as “Hold” with a price target of $307.16, reports MarketBeat. The average price target suggests a potential upside of 0.82% from the latest price.
Essex Property is also one of the 12 best self storage and apartment stocks to invest in.
19. United Therapeutics Corporation (NASDAQ:UTHR)
Market Capitalization: $14.06 billion
United Therapeutics Corporation is a biotechnology company focused on developing products for chronic and life-threatening diseases. Its products include treatments for pulmonary arterial hypertension (PAH), such as Tyvaso, Remodulin, and Orenitram, as well as a monoclonal antibody for high-risk neuroblastoma called Unituxin. The company is also developing new treatments for PAH, gene therapy for lung blood vessels, and treatments for idiopathic pulmonary fibrosis, and collaborates with other companies on various drug development projects. It is also one of the 10 best healthcare stocks for long-term investment.
For the full year of 2024, United Therapeutics reported record revenues of $2.88 billion, reflecting 24% growth over 2023. Net income amounted to $1.2 billion, compared to $984.8 million in 2023.
In March, three insiders, including the president and COO, sold approximately $169.38 million worth of United Therapeutics shares at an average price of $317.20 per share. Currently, the stock trades at $312.31 per share, having declined 11.49% year-to-date. However, over the past 12 months, United Therapeutics shares returned 26.00% to its investors.
According to StockAnalysis, 12 analysts rate United Therapeutics stock as “Buy.” The 12-month stock price target is $388.25, representing a potential upside of 24.18% from the latest price.
18. The Cigna Group (NYSE:CI)
Market Capitalization: $86.62 billion
Cigna is a global health services company offering insurance and healthcare solutions for individuals, employers, and government organizations. It ranks 19th among the 20 priciest stocks insiders have been selling in March. The Bloomfield, Connecticut-based company provides services in areas like medical, dental, life, disability, and pharmacy benefits, with a focus on managed care. Through its Evernorth subsidiary, the company is expanding into health services, pharmacy benefit management, and digital health solutions. Cigna is also one of the 10 best undervalued stocks to buy according to billionaires.
In recent developments, Cigna confirmed the successful completion of the sale of its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation (HCSC). The divestment of these assets should streamline the company’s portfolio and enable it to drive further innovation to support customers.
This month, four insiders, including the CEO, sold around $3.18 million worth of Cigna shares at an average price of $320.00 per share. Year-to-date, the stock is up 15.66%, trading at $319.39 per share. However, over the past 12 months, Cigna shares lost 10.72%.
TipRanks reports that 19 analysts rate Cigna stock as a “Strong Buy” with a price target of $366.22. The average price target suggests a potential upside of 14.62% from the latest price.
17. Curtiss-Wright Corporation (NYSE:CW)
Market Capitalization: $12.77 billion
Curtiss-Wright Corp provides engineered products and services for the aerospace, defense, and industrial sectors. It ranks 17th among the top 20 stocks insiders are dumping in March. The company operates in three areas: defense electronics, aerospace and industrial, and naval and power. With about 8,000 employees, Curtiss-Wright focuses on creating innovative solutions, drawing inspiration from the legacy of Glenn Curtiss and the Wright brothers.
For the year ending Dec. 31, 2024, the company reported sales of $3.1 billion, up from $2.85 billion in 2023. Operating income for the year was $529 million, compared to $484 million in the previous year.
On February 5, the company announced that its board of directors declared a quarterly dividend of $0.21 per share on Curtiss-Wright common stock.
This month, eight insiders, including the chair and CEO, CFO, and COO sold approximately $2.09 million worth of Curtiss-Wright shares at an average price of $325.49 per share. Since the beginning of the year, the stock dropped 4.26%, trading at $339.77. However, over the past 12 months, Curtiss-Wright shares returned 35.25%.
According to six analysts, the average rating for CW stock is “Buy.” The 12-month stock price forecast is $382.67, which is an increase of 13.02% from the latest price.
Curtiss-Wright Corporation is also one of the 11 best American defense stocks to buy now.
16. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Market Capitalization: $7.47 billion
Madrigal is a biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH). The company’s Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to treat MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial is evaluating Rezdiffra for treating compensated MASH cirrhosis.
For the full year 2024, the company reported net revenues of $180.1 million. No product sales were recognized during the comparable prior year period. As of Dec. 31, 2024, Madrigal had cash, cash equivalents, restricted cash and marketable securities of $931.3 million, compared to $634.1 million at Dec. 31, 2023.
In recent developments, Madrigal announced FDA approval of Rezdiffra for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
This month, five insiders, including the CFO, sold approximately $11.36 million worth of Madrigal shares at an average price of $330.33 per share. Currently, the stock trades at $338.49 per share, having gained 9.69% year-to-date and 36.70% over the past 12 months.
Ten analysts have given an average “Moderate Buy” rating on Madrigal stock with a price target of $378.44. The average price target suggests a potential upside of 11.79% from the latest price.
15. Enstar Group Limited (NASDAQ:ESGR)
Market Capitalization: $4.95 billion
Enstar Group is a global insurance group that provides innovative insurance solutions through its network of companies in major insurance hubs like Bermuda, the US, London, Europe, and Australia. The Hamilton, Bermuda-based company focuses on improving net book value per share by acquiring and managing insurance and reinsurance companies in run-off. Enstar was previously known as Castlewood Holdings Limited and changed its name in 2007.
In March, three insiders sold around $5.15 million worth of Enstar shares at an average price of $332.02 per share. Currently, the stock trades at $332.33 per share, having risen 3.19% year-to-date and 11.15% over the past 12 months.
Analyst coverage for Enstar stock is currently limited.
14. Trane Technologies plc (NYSE:TT)
Market Capitalization: $81.60 billion
Trane Technologies designs and manufactures solutions for heating, ventilation, air conditioning, and refrigeration. The Swords, Ireland-headquartered company offers a wide range of products, including air conditioners, heat pumps, chillers, dehumidifiers, energy-efficient systems, and transport refrigeration. It was founded in 1885 and was previously known as Ingersoll-Rand Plc before changing its name in March 2020.
For the full year 2024, Trane Technologies reported revenue of $19.8 billion, up 12% year-over-year. GAAP operating margin was up 120 bps from 2024. Bookings were $20.3 billion, up 11% year-over-year, led by Americas Commercial HVAC.
This month, five insiders, including the CEO, sold approximately $16.03 million worth of Trane Technologies shares at an average price of $347.57 per share. Since the beginning of the year, the stock lost 1.48% trading at $363.88 per share. However, over the past 12 months, Trane Technologies returned 21.59% to its investors.
Twelve Wall Street analysts rate Trane Technologies stock as “Hold” with a price target of $424.55, according to TipRanks. The average price target suggests a potential upside of 16.57%.
Trane Technologies is also one of the 10 best European stocks to buy according to billionaires.
13. CrowdStrike Holdings, Inc. (NASDAQ:CRWD)
Market Capitalization: $93.23 billion
The 13th stock among the 20 most expensive stocks insiders are dumping in March is a cybersecurity firm, CrowdStrike. The Austin, Texas-based company offers a range of services, including endpoint and cloud security, identity protection, and AI-powered automation, primarily through its Falcon platform. It is also one of the 11 AI stocks shaking up Wall Street today.
For the full fiscal year of 2025, CrowdStrike reported revenue of $3.95 billion, a 29% increase from fiscal 2024. Subscription revenue was $3.76 billion, up 31% from the prior year. GAAP net loss amounted to $19.3 million, compared to income of $89.3 million in fiscal 2024. Net cash generated from operations was $1.38 billion, compared to $1.17 billion in fiscal 2024. Free cash flow was $1.07 billion, compared to $938.2 million in fiscal 2024.
This month, six insiders, including the president and CEO, CFO, and CSO, sold around $25.88 million worth of CrowdStrike shares at an average price of $368.87 per share. Currently, the stock trades at $377.33 per share, having gained 10.28% year-to-date, and 14.34% over the past 12 months.
Based on 43 analysts’ estimates, CrowdStrike stock is a “Moderate Buy,” with a price target of $400.26 per share. The average price target suggests a potential upside of 6.01% from the latest price.
12. FactSet Research Systems Inc. (NYSE:FDS)
Market Capitalization: $16.71 billion
FactSet Research operates as a financial digital platform and enterprise solutions provider for the global investment community. The Norwalk, Connecticut-based company offers workstations, portfolio analytics, data solutions, and managed services to support investment professionals in managing and analyzing portfolios.
For the second quarter of fiscal 2025, FactSet reported revenues of $570.66 million, compared to $545.95 million in the same period of fiscal 2024. Net income was $144.86 million, compared to $140.94 million in the corresponding quarter of the previous year. EBITDA amounted to $224.65 million, compared to $216.83 million in the second quarter of fiscal 2024.
In March, three insiders, including the CEO and CTO, sold a total of $2.29 million worth of FactSet shares at an average price of $433.43 per share. Currently, the stock trades at $441.43 per share, having dropped 8.09% year-to-date and 0.55% over the past 12 months.
According to StockAnalysis, 10 analysts rate FactSet Research stock as “Sell,” with a price target of $442.1. The average price target suggests a decrease of 0.25% from the latest price.
11. Domino’s Pizza, Inc. (NASDAQ:DPZ)
Market Capitalization: $15.79 billion
Domino’s Pizza is an American multinational pizza chain founded in 1960 and headquartered in Ann Arbor, Michigan. It operates over 15,000 stores worldwide, offering pizzas and a variety of other food items like wings, pasta, and desserts. The company operates through U.S. stores, international franchises, and its supply chain segment.
For the fourth quarter of 2024, Domino’s Pizza disclosed a revenue increase of $40.09 million from the revenue in the fourth quarter of 2023. The company attributes the revenue growth to higher supply chain and U.S. franchise advertising revenues. Net income grew $12.2 million compared to the same period of 2023. Diluted earnings per share were $4.89 in the fourth quarter of 2024, compared to $4.48 in the fourth quarter of 2023, representing a $0.41 or 9.2% increase.
In February, the company’s board of directors approved a 15% increase in its quarterly dividend, declaring a dividend of $1.74 per share on its outstanding common stock.
This month, five insiders, including the CFO, sold approximately $7.32 million worth of Domino’s Pizza shares at an average price of $460.14 per share. Year-to-date, the stock is up 9.65%, trading at $460.27. Over the past 12 months, Domino’s Pizza’s shares dropped 4.71%.
Based on 28 analysts’ estimates, Domino’s Pizza stock is a “Moderate Buy” with a price target of $503.41, reports MarketBeat. The average price target represents a potential upside of 9.37% from the latest price.
Domino’s Pizza is also one of the 10 best delivery stocks to buy according to billionaires.
10. Moody’s Corporation (NYSE:MCO)
Market Capitalization: $85.85 billion
Moody’s Corporation ranks 10th among the 20 most expensive stocks insiders are dumping in March. This is a global risk assessment firm with two main segments: Moody’s Analytics and Moody’s Investors Service. Moody’s Analytics offers risk management tools and services, including credit research and data sets, while Moody’s Investors Service provides credit ratings and assessments for debt obligations. Founded in 1900 and headquartered in New York, the company was formerly known as Dun and Bradstreet. It is also one of the 10 best Warren Buffett stocks to buy right now.
This month, three insiders, including the president and CEO, sold a total of $4.37 million of Moody’s shares at an average price of $478.82 per share. The stock now trades at $477.24 having risen 0.82% year-to-date and 22.08% over the past 12 months.
According to TipRanks, thirteen Wall Street analysts have rated Moody’s as a “Moderate Buy” with a price target of $555.38. The average price target suggests a 15.95% upside from the latest price.
9. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Market Capitalization: $130.72 billion
Vertex Pharmaceuticals is a biotechnology company focused on developing therapies for cystic fibrosis (CF) and other diseases. It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston, Massachusetts-based company collaborates with CRISPR Therapeutics, Moderna, and Entrada Therapeutics, and sells its products through specialty pharmacies and distributors.
For the full year 2024, Vertex disclosed product revenue of $11.02 billion, up 12% year-over-year. The revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO. Net product revenue increased 11% to $4.34 billion outside the U.S. on strong patient demand in both established and newer markets. GAAP net loss and non-GAAP net income were $536 million and $111 million, respectively, compared to GAAP net income of $3.6 billion and non-GAAP net income of $4.0 billion, respectively, for 2023.
For the full year 2025, Vertex projects revenue to be in the range of $11.75 billion to $12 billion.
In recent developments, Vertex announced that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval for ALYFTREK, a once-daily treatment for cystic fibrosis. It is for people aged 6 and older with at least one F508del mutation or another responsive mutation in the CFTR gene.
In March, three insiders, including the CSO and CFO sold approximately $10.09 million worth of Vertex Pharmaceuticals shares at an average price of $497.58 per share. Year-to-date, the stock is up 26.41%, trading at $509.04 per share. Over the past 12 months, its shares returned 21.65%.
Twenty-six analysts rate Vertex as “Moderate Buy” with a price target of $506.70 per share, according to MarketBeat. The average price target suggests a downside of 0.46% from the latest price.
Read here what Mad Money host Jim Cramer recently said about Vertex stock.
8. Thermo Fisher Scientific Inc. (NYSE:TMO)
Market Capitalization: $194.04 billion
Thermo Fisher provides a wide range of life sciences solutions, analytical instruments, diagnostics, laboratory products, and biopharma services globally. Its offerings include products for biological research, drug and vaccine production, clinical diagnostics, and laboratory research across various industries. The Waltham, Massachusetts-headquartered company operates under several brands such as Thermo Scientific, Invitrogen, and Applied Biosystems.
For the full year 2024, Thermo Fisher disclosed revenue of $42.88 billion, flat compared to 2023. Full year GAAP diluted earnings per share (EPS) grew 7% to $16.53.
In recent developments, Thermo Fisher launched the Thermo Scientific Vulcan Automated Lab, a system designed to improve productivity and yield, and reduce costs for semiconductor manufacturers. The solution aims to address the growing demand for advanced metrology data in semiconductor manufacturing as technologies become more complex. Marc N. Casper, CEO of Thermo Fisher, emphasized the company’s expertise in electron microscopy and AI to help semiconductor manufacturers enhance efficiency.
In March, three insiders, including the chairman and CEO, sold around $12.28 million worth of Thermo Fisher shares at an average price of $520.17 per share. The stock currently trades at $514.34 per share, having lost 1.13% year-to-date, and 9.58% over the past 12 months.
Based on 18 Wall Street analysts’ ratings, Thermo Fisher stock is a “Strong Buy” with a price target of $662.00. According to TipRanks, the average price target represents a 28.71% upside from the latest price.
Thermo Fisher is also one of the 12 best diagnostics stocks to invest in right now.
7. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Market Capitalization: $186.24 billion
The seventh among the 20 most expensive stocks insiders are dumping in March is Intuitive Surgical, which develops and markets products that improve minimally invasive care, including the da Vinci Surgical System and Ion endoluminal system for surgeries and diagnostics. The Sunnyvale, California-based company also offers surgical instruments, training, and support services to healthcare providers.
For the fourth quarter of 2024, Intuitive Surgical reported revenue of $2.41 billion, up 25% from $1.93 billion in the same period of 2023. The higher fourth-quarter revenue, Intuitive Surgical attributed to growth in da Vinci procedure volume and an increase in the installed base of systems. GAAP net income was $686 million, or $1.88 per diluted share, compared with $606 million, or $1.69 per diluted share, in the same period of 2023. The company ended the fourth quarter of 2024 with $8.83 billion in cash, cash equivalents, and investments, an increase of $521 million during the quarter, primarily driven by cash generated from operations and partially offset by capital expenditures.
In March, six insiders, including the CMO, sold around $24.92 million worth of Intuitive Surgical shares at an average price of $523.58 per share. Currently, the stock trades at $519.81 per share, having declined 0.41% since the beginning of the year. However, over the past 12 months, its shares returned 30.73%.
According to 19 analysts, the average rating for Intuitive Surgical stock is “Strong Buy,” reports StockAnalysis. The average price target of $577.5 suggests an 11.13% upside from the latest price.
Intuitive Surgical is also among the 10 high-valuation stocks to buy according to billionaires.
6. Mastercard Incorporated (NYSE:MA)
Market Capitalization: $497.03 billion
Mastercard is a global payment technology company that provides transaction processing and payment-related products and services. It offers solutions for consumers, businesses, financial institutions, and governments, including payment products, prepaid services, and bill payment solutions. The Purchase, New York-headquartered company also provides security services, advanced analytics, and cross-border payment solutions. Mastercard operates under the Mastercard, Maestro, and Cirrus brands. It is also one of the 10 best stocks to buy now for the long term.
For the full year 2024, Mastercard reported revenue of $28.2 billion, up 12% year-over-year. Net income amounted to $12.9 billion, up 15% from the prior year. Diluted earnings per share were $13.89, which is 17% higher than in 2023.
This month, three insiders, including the president and CEO, and CTO, sold approximately $19.71 million worth of Mastercard shares at an average price of $548.11 per share. The stock gained 3.53% since the beginning of the year, and 14.34% over the past 12 months, currently trading at $545.16 per share.
Thirty analysts rate Mastercard stock as a “Moderate Buy” with the average price target of $606.11. The average price target suggests a potential upside of 11.27% from the latest price, according to MarketBeat.
5. Intuit Inc. (NASDAQ:INTU)
Market Capitalization: $172.97 billion
Intuit, a financial technology company based in California, ranks fifth among the 20 most expensive stocks insiders have recently been dumping. The company is known for its popular products like TurboTax for tax preparation, Credit Karma for credit monitoring and personal finance, and QuickBooks, an accounting tool for small businesses. Intuit operates offices in seven countries worldwide.
In recent developments, Intuit launched Tap to Pay on iPhone for its QuickBooks Online customers in the U.S. This new feature allows small and mid-market businesses to securely accept in-person contactless payments using just an iPhone, offering an easy way to manage finances, get paid faster, and support business growth.
In 2024, Intuit reported revenues of $8.75 billion, reflecting a 7% increase from the previous year. However, net income attributable to common stockholders dropped 16% to $815 million. Adjusted EBITDA reached $4.1 billion, showing a 160 basis-point improvement compared to the previous year.
This month, four insiders, including the company’s founder, sold approximately $59.47 million worth of Intuit shares at an average price of $588.29 per share. The stock is down 1.56% year-to-date and 3.33% over the past 12 months, trading at $618.72 per share.
Based on data from TipRanks and 20 Wall Street analysts, Intuit has an average rating of “Strong Buy” with a 12-month price target of $720.89. The average price forecast suggests a 16.51% potential increase from the latest price.
4. Equinix, Inc. (NASDAQ:EQIX)
Market Capitalization: $81.88 billion
Equinix, based in Redwood City, California, is one of the largest third-party data center providers globally. The company specializes in data center operations, offering services such as colocation, interconnection, and internet connectivity, all through a neutral platform that facilitates seamless data exchange between networks. With 268 data centers across 34 countries and 33.7 million square feet of space, Equinix operates on every major continent. Equinix is also one of the 20 best data center stocks to buy according to billionaires.
In 2024, Equinix reported revenue of $8.75 billion, a 7% increase from the previous year. However, net income attributable to common stockholders fell by 16% to $815 million. Adjusted EBITDA reached $4.1 billion, marking a 160 basis-point improvement year-over-year.
In March, eight insiders, including the president and CEO, and CFO, sold a total of $5.39 million worth of Equinix shares at an average price of $860.15 per share. The stock now trades at $841.22 per share, having dropped 10.78% year-to-date. Over the past 12 months, Equinix returned 5.14% to its investors.
According to 19 analysts, the average rating for Equinix stock is “Buy,” reports StockAnalysis. The 12-month stock price target is $972.22, representing a potential upside of 15.56% from the latest price.
3. Costco Wholesale Corporation (NASDAQ:COST)
Market Capitalization: $412.74 billion
Costco operates membership-only warehouse clubs in various countries, including the U.S., Canada, Mexico, Japan, and several others. The Issaquah, Washington-based company offers a wide range of products, from groceries and electronics to furniture and clothing, and also provides services like gas stations, pharmacies, and tire installation. Costco generates significant profit through membership fees, which totaled $4.8 billion in fiscal 2024, and has seen a 7% annual increase in paid members over the last two years.
For the second quarter of fiscal 2025, Costco disclosed net sales of $62.53 billion, up 9.1% from $57.33 billion in fiscal 2024. Net income for the quarter was $1,788 million, $4.02 per diluted share, compared to $1,743 million, $3.92 per diluted share, last year.
In January, Costco’s board of directors declared a quarterly cash dividend on its common stock of $1.16 per share.
This month, three insiders, including the CEO, sold around $4.95 million worth of Costco shares at an average price of $917.94 per share. Year-to-date, the stock is up 1.53%, trading at $930.26 per share. Over the past 12 months, Costco returned 27.26% to its investors.
Twenty-nine analysts have given an average “Moderate Buy” rating to Costco stock with a price target of $1,029.00 per share. According to MarketBeat, the average price target suggests a potential upside of 10.61% from the latest price.
Commenting on consumer-oriented stocks that can work in a slowdown, Mad Money host Jim Cramer recently mentioned Costco and said, “Once people get locked to a great service, they almost never cancel, whether it be Costco, Amazon Prime, Netflix.”
Costco is also one of the 10 best department store stocks to invest in.
2. TransDigm Group Incorporated (NYSE:TDG)
Market Capitalization: $78.19 billion
TransDigm is an aerospace company that manufactures engineered components for both commercial and military aircraft. The Cleveland, Ohio-headquartered company recently acquired Raptor Scientific for $655 million, which is expected to drive future revenue growth. TransDigm offers products across three main segments: Power & Control, Airframe, and Non-Aviation, serving a wide range of customers, including airlines, military agencies, and equipment suppliers. The stock is also one of the 11 best American defense stocks to buy now.
For the first quarter of fiscal 2025, TransDigm reported a net income of $493 million, up 29% from last year, driven by a 12% year-over-year surge in net sales. Adjusted earnings per share were $7.83, growing 9% from the prior year’s quarter.
This month, four insiders, including the president and CEO, COO, and CCO, sold approximately $159.01 million worth of TransDigm shares at an average price of $1,342.48 per share. Currently, the stock trades at $1,394.11 per share, having rose 10.01% year-to-date and 13.98% over the past 12 months.
Based on 11 Wall Street analysts’ ratings, Transdigm stock is a “Strong Buy,” with an average price target of $1,527.45. According to TipRanks, the average price target suggests a 9.56% upside from the latest price.
1. AutoZone, Inc. (NYSE:AZO)
Market Capitalization: $61.43 billion
AutoZone is a leading retailer and distributor of automotive replacement parts and accessories, serving customers in the US, Mexico, and Brazil. It ranks first among the 20 most expensive stocks insiders are dumping in March. The Memphis, Tennessee-based company offers a wide variety of products, ranging from essential maintenance items to specialized parts and accessories. AutoZone serves both do-it-yourself (DIY) customers and professional mechanics through a variety of sales channels, including online platforms and commercial programs.
This month, AutoZone disclosed net sales of $4.0 billion for its second quarter ended Feb. 15, 2025, an increase of 2.4% from the second quarter of fiscal 2024. For the quarter, gross profit, as a percentage of sales, was flat to last year at 53.9%. Operating profit decreased 4.9% to $706.8 million. Net income for the quarter decreased 5.3% over the same period last year to $487.9 million, while diluted earnings per share decreased 2.1% to $28.29.
In March, four insiders, including the senior vice president and CIO, sold a total of $17.01 million worth of AutoZone shares at an average price of $3,565.67 per share. The stock is now trading at $3,672.23 per share, having gained 15.69% year-to-date, and 15.06% over the past 12 months.
According to 20 analysts, AutoZone stock has an average rating of “Strong Buy,” reports StockAnalysis. The 12-month price target is $3,717.70, indicating a 1.16% increase from the current price.
AutoZone is also one of the 12 stocks to buy that may be splitting soon.
Overall, AZO is first among the 20 most expensive stocks insiders are dumping in March. While we acknowledge the potential of AZO our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
